

## Forteo® (teriparatide) - First-time generic

- On November 17, 2023, <u>Teva announced</u> the FDA approval of an AB-rated generic version of Eli Lilly's Forteo (teriparatide) subcutaneous injection.
  - Teva's generic Forteo is expected to be available in the coming weeks.
- Forteo is approved:
  - For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy
  - To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy and
  - For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.
- Teriparatide is also available as a subcutaneous injection by <u>Alvogen</u> and carries the same indications as Forteo.
- According to IQVIA data, Forteo had annual sales of \$609 million as of July 2023.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.